X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.

Yunjae Kim | Gihyeon Kim | Sujeong Kim | Beomki Cho | Sang-Yeob Kim | Eun-Ju Do | Dong-Jun Bae | Seungil Kim | Mi-Na Kweon | Joon Seon Song | Sang Hyoung Park | Sung Wook Hwang | Mi-Na Kim | Yeongmin Kim | Kyungchan Min | Sung-Han Kim | Mark D Adams | Charles Lee | Hansoo Park | Sook Ryun Park
Cell host & microbe | 2024

The gut microbiome significantly influences immune responses and the efficacy of immune checkpoint inhibitors. We conducted a clinical trial (NCT04264975) combining an anti-programmed death-1 (PD-1) inhibitor with fecal microbiota transplantation (FMT) from anti-PD-1 responder in 13 patients with anti-PD-1-refractory advanced solid cancers. FMT induced sustained microbiota changes and clinical benefits in 6 of 13 patients, with 1 partial response and 5 stable diseases, achieving an objective response rate of 7.7% and a disease control rate of 46.2%. The clinical response correlates with increased cytotoxic T cells and immune cytokines in blood and tumors. We isolated Prevotella merdae Immunoactis from a responder to FMT, which stimulates T cell activity and suppresses tumor growth in mice by enhancing cytotoxic T cell infiltration. Additionally, we found Lactobacillus salivarius and Bacteroides plebeius may inhibit anti-tumor immunity. Our findings suggest that FMT with beneficial microbiota can overcome resistance to anti-PD-1 inhibitors in advanced solid cancers, especially gastrointestinal cancers.

Pubmed ID: 39059396 RIS Download

Additional research tools detected in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


CD8+ T Cell Isolation Kit, human (antibody)

RRID:AB_3073903

This cocktail targets CD4, CD15, CD16, CD19, CD34, CD36, CD56, CD123, TCRγ/δ, CD235a (Glycophorin A)

View all literature mentions

CD4+ T Cell Isolation Kit, human (antibody)

RRID:AB_2916089

This cocktail targets CD8, CD14, CD15, CD16, CD19, CD36, CD56, CD123, TCR γ/δ, CD235a (Glycophorin A).

View all literature mentions

FoxP3 (antibody)

RRID:AB_2737940

This monoclonal targets FoxP3

View all literature mentions

CD11b (Mac-1) (antibody)

RRID:AB_2744272

This monoclonal targets CD11b (Mac-1)

View all literature mentions

CD11c (antibody)

RRID:AB_2737789

This monoclonal targets CD11c

View all literature mentions

CD44 (antibody)

RRID:AB_2738517

This monoclonal targets CD44

View all literature mentions

BV510 Rat Anti-Mouse CD8a Antibody (antibody)

RRID:AB_2687548

This monoclonal targets Mouse CD8a

View all literature mentions

APC anti-mouse TNF-alpha (antibody)

RRID:AB_315429

This monoclonal targets TNF-alpha

View all literature mentions

BV421 Rat Anti-Mouse F4/80 (antibody)

RRID:AB_2734779

This monoclonal targets F4/80

View all literature mentions

PE anti-mouse IFN-gamma (antibody)

RRID:AB_2890730

This monoclonal targets IFN-gamma

View all literature mentions

APC anti-mouse CD25 (antibody)

RRID:AB_2280288

This monoclonal targets CD25

View all literature mentions

PE anti-mouse CD279 (PD-1) (antibody)

RRID:AB_313421

This monoclonal targets CD279

View all literature mentions

APC anti-mouse CD62L (antibody)

RRID:AB_313099

This monoclonal targets CD62L

View all literature mentions

InVivoPlus anti-mouse PD-1 (CD279) (antibody)

RRID:AB_10949053

This monoclonal targets PD-1 (CD279)

View all literature mentions

InVivoPlus rat IgG2a isotype control (antibody)

RRID:AB_1107769

This isotype control targets Trinitrophenol

View all literature mentions

C57BL/6-Tg(TcraTcrb)1100Mjb/J (organism)

RRID:IMSR_JAX:003831

Mus musculus with name C57BL/6-Tg(TcraTcrb)1100Mjb/J from IMSR.

View all literature mentions

BALB/cAnNCrlCrlj (organism)

RRID:MGI:6323059

laboratory mouse with name BALB/cAnNCrlCrlj from MGI.

View all literature mentions

C57BL/6NCrlCrlj (organism)

RRID:MGI:5882838

laboratory mouse with name C57BL/6NCrlCrlj from MGI.

View all literature mentions

4T1 (cell line)

RRID:CVCL_0125

Cell line 4T1 is a Cancer cell line with a species of origin Mus musculus (Mouse)

View all literature mentions

MC-38 (cell line)

RRID:CVCL_B288

Cell line MC-38 is a Cancer cell line with a species of origin Mus musculus

View all literature mentions